drugset / Trial / NCT00379600

The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

NCT00379600

Phase 2 Completed 96 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying Anti-Rheumatic Drug (DMARD) treatment does not give adequate relief.

Timeline

Start
2004-11
Primary completion
2006-12
Completion
2006-12

Publications

  • Background This study has not been published in the scientific literature.

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 8 mg

Indications